The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
Year: 2020
Type: article
Abstract: Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.
Institutions: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Virginia Cancer Specialists, University of Chicago, National Institutes of Health, National Heart, Lung, and Blood Institute, Memorial Sloan Kettering Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, City Of Hope National Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute, Mayo Clinic, University of Minnesota, Masonic Cancer Center, Emory University, Winship Cancer Institute
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W3093301124